Vaccine compositions for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof are disclosed. The composition comprises (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and (c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.本發明提供用以在需治療患者身上誘發經強化之抗原特異性T細胞介導免疫反應之疫苗組成物。該組成物包含(a)一治療有效量之一免疫原性蛋白質,其係包含至少一病原體的一抗原;(b)一皂素基佐劑(saponin-base adjuvant),其係選自以下項目所構成群組:GPI-0100、Quil A及QS-21;以及(c)一類鐸受體致效佐劑[Toll-like receptor (TLR) agonist adjuvant],其係選自以下項目所構成群組:單磷醯脂質A(MPL)及CpG1826。